Aquila has established specialised immuno-oncology in vitro protocols to assess the ability of antibodies/compounds to modulate the effector function of immune cell subsets and initiate a killing response (apoptosis) towards cultured tumour cells. It is designed as a T cell (or NK cell) killing assay. This can be established either as a cytotoxic T cell assay or an antibody dependant cell-mediated cytotoxicity (ADCC) assay (NK cells).
Target tumour cells are labelled with NucLightTM Red (for tumour cell counting) and seeded into a 96-well plate, and treated with caspase 3/7 along with compounds under investigation. Immune cells are added (either as PBMC, CD8+ or NK cells, depending on target of choice) and the plate is incubated in the IncuCyte ZOOM® for a defined period of time. This technology allows real-time visualisation and automated analysis of immune cell-mediated killing of tumour cells.
Contact us to discuss your T cell killing assay study requirements.